Scientific evaluation and optimization of treatment paths, times and content as part of the extended adjuvant endocrine therapy of patients with early breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034033

Enrollment

Registered

2024-11-14

Start date

2024-01-29

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50

Interventions

Group 1: Analysis and comparison of the supply chain and processes in the care of patients receiving extended adjuvant therapy in a breast center, a medical care center (MVZ) or an oncology practice

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: a) Patients receiveing adjuvant oral tumor therapy with abemaciclib for 2 years b) Patients presented to the gyneco-oncological tumor board between 11/2022 and 10/2023 and started the extended adjuvant oral tumor therapy (for the collection of retrospective data). c) The presentation in the gyneco-oncology consultation takes place in the breast center of the KUM, in a MVZ or an external practice

Exclusion criteria

Exclusion criteria: a) Patients with indications other than mentioned

Design outcomes

Primary

Measure	Time frame
Analysis of current state and development of concrete suggestions for optimizing treatment and therapy management in early breast cancer	—

Secondary

Measure	Time frame
a) Recording the different patient's path from diagnosis to the start of extended adjuvant therapy b) Presentation of differences in interfaces from the perspective of breast center as well as from the perspective of the patients and practitioners (administrative, medical, nursing) on ??site in the settings: • Breast center and oncological therapy in one hand (gynecological oncology) • Medical care center (MVZ) c) Recording the effort and special features for the extended adjuvant therapy (up to 2 years) as well as special features in the setting of oral tumor therapy and definition of wishes for these treatment paths by patients, relatives, practicing specialists, employees inside the breast center and the oncology departments (breast center, MVZ, oncology practice). d) Clarification of needed information of those involved in treatment route at various time points: • Indication • Start of therapy • Therapy sequencing (postoperative, local and systemic) • Therapy implementation and support including side effect management and special features of patients´ situation in the adjuvant/curative setting • Analysis of therapy discontinuations in the context of extended adjuvant setting	—

Measure

Time frame

a) Recording the different patient's path from diagnosis to the start of extended adjuvant therapy b) Presentation of differences in interfaces from the perspective of breast center as well as from the perspective of the patients and practitioners (administrative, medical, nursing) on ??site in the settings: • Breast center and oncological therapy in one hand (gynecological oncology) • Medical care center (MVZ) c) Recording the effort and special features for the extended adjuvant therapy (up to 2 years) as well as special features in the setting of oral tumor therapy and definition of wishes for these treatment paths by patients, relatives, practicing specialists, employees inside the breast center and the oncology departments (breast center, MVZ, oncology practice). d) Clarification of needed information of those involved in treatment route at various time points: • Indication • Start of therapy • Therapy sequencing (postoperative, local and systemic) • Therapy implementation and support including side effect management and special features of patients´ situation in the adjuvant/curative setting • Analysis of therapy discontinuations in the context of extended adjuvant setting

—

Countries

Germany

Contacts

Public ContactFranziska Henze

LMU Klinikum, Brustzentrum

franziska.henze@med.uni-muenchen.de049089440077996

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026